Search research articles
Contact Us
Filters
Showing results (151-160 of 196) with videos related to
Page
of 20
Sort By:
BJUI Compass
|
January 29, 2025
The impact of preoperative venous thromboembolism on patients undergoing TURBT: Perioperative outcomes and healthcare costs from US insurance claims data
Anas S Tresh, Francesco Del Giudice, Shufeng Li, et al.
BJU International
|
July 9, 2025
Impact of timing of computed tomography staging and patient factors on the detection of 'true' cN+ bladder cancer
Markus von Deimling, Marc Furrer, Alberto Bianchi, et al.
Targeted Oncology
|
November 13, 2024
Adjuvant Immune Checkpoint Inhibitors for Muscle-Invasive Urothelial Carcinoma: An Updated Systematic Review, Meta-analysis, and Network Meta-analysis
Takafumi Yanagisawa, Keiichiro Mori, Akihiro Matsukawa, et al.
Frontiers in Immunology
|
March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
Cancer Immunology, Immunotherapy : CII
|
June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
Lorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
Cancer Immunology, Immunotherapy : CII
|
May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Camillo Porta, Francesco Massari, Tarek Taha, et al.
Targeted Oncology
|
May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
BJU International
|
October 31, 2023
Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node-positive bladder cancer
Markus von Deimling, Marc Furrer, Laura S Mertens, et al.
NPJ Precision Oncology
|
July 3, 2023
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system
Kai Zimmer, Florian Kocher, Gerold Untergasser, et al.
Clinical & Experimental Metastasis
|
November 21, 2025
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study
Renate Pichler, Gerald Klinglmair, Kirstin Binz, et al.
Page
of 20
Search research articles
Search
Showing results (151-160 of 196) with videos related to
Sort By:
Page
of 20
BJUI Compass
|
January 29, 2025
The impact of preoperative venous thromboembolism on patients undergoing TURBT: Perioperative outcomes and healthcare costs from US insurance claims data
Anas S Tresh, Francesco Del Giudice, Shufeng Li, et al.
BJU International
|
July 9, 2025
Impact of timing of computed tomography staging and patient factors on the detection of 'true' cN+ bladder cancer
Markus von Deimling, Marc Furrer, Alberto Bianchi, et al.
Targeted Oncology
|
November 13, 2024
Adjuvant Immune Checkpoint Inhibitors for Muscle-Invasive Urothelial Carcinoma: An Updated Systematic Review, Meta-analysis, and Network Meta-analysis
Takafumi Yanagisawa, Keiichiro Mori, Akihiro Matsukawa, et al.
Frontiers in Immunology
|
March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
Cancer Immunology, Immunotherapy : CII
|
June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
Lorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
Cancer Immunology, Immunotherapy : CII
|
May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Camillo Porta, Francesco Massari, Tarek Taha, et al.
Targeted Oncology
|
May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
BJU International
|
October 31, 2023
Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node-positive bladder cancer
Markus von Deimling, Marc Furrer, Laura S Mertens, et al.
NPJ Precision Oncology
|
July 3, 2023
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system
Kai Zimmer, Florian Kocher, Gerold Untergasser, et al.
Clinical & Experimental Metastasis
|
November 21, 2025
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study
Renate Pichler, Gerald Klinglmair, Kirstin Binz, et al.
Page
of 20